Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592628511> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2592628511 abstract "588 Background: The aim was to provide an endocrine therapy option against advanced (ABC) or recurrent breast cancer (RBC) in premenopausal women. We conducted an exploratory phase II trial in combination with an LH-RH analogue (LH-RHa) and an aromatase inhibitor (AI) to assess the efficacy and tolerability after failure of standard LH-RHa plus tamoxifen (TAM). Methods: Premenopausal patients (pts) with ER+ and/or PgR+ ABC or RBC refractory to LH-RHa + TAM were treated with LH-RHa (goserelin: GOS) and AI (anastrozole: ANA). The primary endpoint was an objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR) based on RECIST, and safety assessed using CTCAE ver. 3.0. Pts with only bone legions were assessed using the criteria by Japanese Breast Cancer Society (14th Ed.). Local assessment (CR, PR or long SD of 24 weeks or longer) was confirmed independently by two radiologists. Results: Between September 2008 and November 2010, 37 pts were enrolled at 10 clinical institutions in Japan. Eleven had recurrence either during, or within one year after the end of adjuvant GOS + TAM (including GOS + TAM followed by only TAM). The disease progressed in 26 women during GOS + TAM. Mean age and BMI were 43.5 years and 22.2 kg/m2, respectively. Thirty-five pts (94.6%) were ER+, and 36 pts (97.3%) were HER2- (one with unknown HER2 status). Non-endocrine treatment included chemotherapy (20 pts; 54%) and radiation therapy (13 pts; 35%). The viscera, soft tissue, and bones were treated in 17, 15 and 14 pts, respectively. Pts with both measurable lesions and bone metastasis, measurable lesions only, and only bone metastasis were 21 (57%), 15 (41%) and 1 (2%), respectively. ORR was 18.9% (95%CI: 8.0-35.2%, 1 CR and 6 PR cases), CBR 62.2% (23 pts, 95%CI: 44.8-77.5%), and median PFS was 7.2 months. Eight pts (21.6%) had adverse events, but none resulted in treatment discontinuation. GOS + ANA was well tolerated. Conclusions: LH-RHa (GOS) + ANA can be a subsequent endocrine treatment for premenopausal pts with ABC or RBC after failure of GOS + TAM." @default.
- W2592628511 created "2017-03-16" @default.
- W2592628511 creator A5008074283 @default.
- W2592628511 creator A5016215778 @default.
- W2592628511 creator A5023097678 @default.
- W2592628511 creator A5024576654 @default.
- W2592628511 creator A5024725726 @default.
- W2592628511 creator A5034042835 @default.
- W2592628511 creator A5038588933 @default.
- W2592628511 creator A5052684223 @default.
- W2592628511 creator A5056628460 @default.
- W2592628511 creator A5084703606 @default.
- W2592628511 creator A5091025405 @default.
- W2592628511 date "2012-05-20" @default.
- W2592628511 modified "2023-09-23" @default.
- W2592628511 title "A multicenter phase II trial of the LH-RH analogue and an aromatase inhibitor combination in premenopausal patients with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: JMTO BC08-01." @default.
- W2592628511 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.588" @default.
- W2592628511 hasPublicationYear "2012" @default.
- W2592628511 type Work @default.
- W2592628511 sameAs 2592628511 @default.
- W2592628511 citedByCount "2" @default.
- W2592628511 countsByYear W25926285112012 @default.
- W2592628511 countsByYear W25926285112013 @default.
- W2592628511 crossrefType "journal-article" @default.
- W2592628511 hasAuthorship W2592628511A5008074283 @default.
- W2592628511 hasAuthorship W2592628511A5016215778 @default.
- W2592628511 hasAuthorship W2592628511A5023097678 @default.
- W2592628511 hasAuthorship W2592628511A5024576654 @default.
- W2592628511 hasAuthorship W2592628511A5024725726 @default.
- W2592628511 hasAuthorship W2592628511A5034042835 @default.
- W2592628511 hasAuthorship W2592628511A5038588933 @default.
- W2592628511 hasAuthorship W2592628511A5052684223 @default.
- W2592628511 hasAuthorship W2592628511A5056628460 @default.
- W2592628511 hasAuthorship W2592628511A5084703606 @default.
- W2592628511 hasAuthorship W2592628511A5091025405 @default.
- W2592628511 hasConcept C121332964 @default.
- W2592628511 hasConcept C121608353 @default.
- W2592628511 hasConcept C126322002 @default.
- W2592628511 hasConcept C142424586 @default.
- W2592628511 hasConcept C143998085 @default.
- W2592628511 hasConcept C2776166826 @default.
- W2592628511 hasConcept C2776215463 @default.
- W2592628511 hasConcept C2777176818 @default.
- W2592628511 hasConcept C2778504769 @default.
- W2592628511 hasConcept C29456083 @default.
- W2592628511 hasConcept C31760486 @default.
- W2592628511 hasConcept C46699223 @default.
- W2592628511 hasConcept C530470458 @default.
- W2592628511 hasConcept C535046627 @default.
- W2592628511 hasConcept C71315377 @default.
- W2592628511 hasConcept C71924100 @default.
- W2592628511 hasConcept C87355193 @default.
- W2592628511 hasConceptScore W2592628511C121332964 @default.
- W2592628511 hasConceptScore W2592628511C121608353 @default.
- W2592628511 hasConceptScore W2592628511C126322002 @default.
- W2592628511 hasConceptScore W2592628511C142424586 @default.
- W2592628511 hasConceptScore W2592628511C143998085 @default.
- W2592628511 hasConceptScore W2592628511C2776166826 @default.
- W2592628511 hasConceptScore W2592628511C2776215463 @default.
- W2592628511 hasConceptScore W2592628511C2777176818 @default.
- W2592628511 hasConceptScore W2592628511C2778504769 @default.
- W2592628511 hasConceptScore W2592628511C29456083 @default.
- W2592628511 hasConceptScore W2592628511C31760486 @default.
- W2592628511 hasConceptScore W2592628511C46699223 @default.
- W2592628511 hasConceptScore W2592628511C530470458 @default.
- W2592628511 hasConceptScore W2592628511C535046627 @default.
- W2592628511 hasConceptScore W2592628511C71315377 @default.
- W2592628511 hasConceptScore W2592628511C71924100 @default.
- W2592628511 hasConceptScore W2592628511C87355193 @default.
- W2592628511 hasLocation W25926285111 @default.
- W2592628511 hasOpenAccess W2592628511 @default.
- W2592628511 hasPrimaryLocation W25926285111 @default.
- W2592628511 hasRelatedWork W1978517459 @default.
- W2592628511 hasRelatedWork W2029440298 @default.
- W2592628511 hasRelatedWork W2041178158 @default.
- W2592628511 hasRelatedWork W2070084966 @default.
- W2592628511 hasRelatedWork W2088094542 @default.
- W2592628511 hasRelatedWork W2090251236 @default.
- W2592628511 hasRelatedWork W2154078032 @default.
- W2592628511 hasRelatedWork W2202899408 @default.
- W2592628511 hasRelatedWork W2242070674 @default.
- W2592628511 hasRelatedWork W2305069085 @default.
- W2592628511 hasRelatedWork W2325879011 @default.
- W2592628511 hasRelatedWork W2343835117 @default.
- W2592628511 hasRelatedWork W2411942897 @default.
- W2592628511 hasRelatedWork W2416668197 @default.
- W2592628511 hasRelatedWork W2440468066 @default.
- W2592628511 hasRelatedWork W2565133593 @default.
- W2592628511 hasRelatedWork W2599971900 @default.
- W2592628511 hasRelatedWork W2972559819 @default.
- W2592628511 hasRelatedWork W3188095088 @default.
- W2592628511 hasRelatedWork W66339914 @default.
- W2592628511 isParatext "false" @default.
- W2592628511 isRetracted "false" @default.
- W2592628511 magId "2592628511" @default.
- W2592628511 workType "article" @default.